CIK 0001061983 · Large accelerated filer
CYTOKINETICS INC
Sign in to watch- Ticker
- CYTK
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 943291317
- Phone
- (650) 624-3000
- Business address
- 350 OYSTER POINT BOULEVARD, ., SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,208,275
- in 16 filings, $12.2M under 10b5-1 plans
Net −$12,208,275. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-12-22 | WIERENGA WENDELL Director | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −20,000 | 0 | ||
| 2025-12-16 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +2,200 | $10.60 | $23K | 140,752 |
| 2025-12-16 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,200 | $61.24 | $135K | 138,552 |
| 2025-12-16 | Malik Fady Ibraham EVP Research & Development | Option exercise · Incentive Stock Option (Right to Buy) 10b5-1 | −2,200 | 0 | ||
| 2025-12-08 | Callos Andrew EVP, Chief Commercial Officer | Option exercise 10b5-1 | +1,042 | $39.13 | $41K | 51,702 |
| 2025-12-08 | Callos Andrew EVP, Chief Commercial Officer | Sale 10b5-1 | −1,042 | $65.96 | $69K | 50,660 |
| 2025-12-08 | Callos Andrew EVP, Chief Commercial Officer | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −1,042 | 35,403 | ||
| 2025-12-05 | Callos Andrew EVP, Chief Commercial Officer | Option exercise 10b5-1 | +15,000 | $23.26 | $349K | 65,660 |
| 2025-12-05 | Callos Andrew EVP, Chief Commercial Officer | Option exercise 10b5-1 | +11,000 | $39.13 | $430K | 76,660 |
| 2025-12-05 | Callos Andrew EVP, Chief Commercial Officer | Option exercise 10b5-1 | +15,858 | $37.63 | $597K | 92,518 |
| 2025-12-05 | Callos Andrew EVP, Chief Commercial Officer | Option exercise 10b5-1 | +10,628 | $37.63 | $400K | 103,146 |
| 2025-12-05 | Callos Andrew EVP, Chief Commercial Officer | Sale 10b5-1 | −52,486 | $65.95 | $3.5M | 50,660 |
| 2025-12-05 | Callos Andrew EVP, Chief Commercial Officer | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −15,000 | 114,000 | ||
| 2025-12-05 | Callos Andrew EVP, Chief Commercial Officer | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −11,000 | 36,445 | ||
| 2025-12-05 | Callos Andrew EVP, Chief Commercial Officer | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −15,858 | 15,857 | ||
| 2025-12-05 | Callos Andrew EVP, Chief Commercial Officer | Option exercise · Incentive Stock Option (Right to Buy) 10b5-1 | −10,628 | 2,657 | ||
| 2025-12-03 | Lee Sung EVP, Chief Financial Officer | Shares withheld for taxes | −1,560 | $65.02 | $101K | 67,917 |
| 2025-12-03 | Callos Andrew EVP, Chief Commercial Officer | Shares withheld for taxes | −1,368 | $65.02 | $89K | 50,660 |
| 2025-12-03 | Malik Fady Ibraham EVP Research & Development | Shares withheld for taxes | −2,058 | $65.02 | $134K | 138,552 |
| 2025-12-03 | Blum Robert I President & CEO | Shares withheld for taxes | −5,930 | $65.02 | $386K | 350,202 |
Page 14 of 22 · 429 trades